Headquartered in New Haven, CT, Achillion is a leading-edge pharmaceutical company advancing multiple candidates with proven mechanisms for the treatment of HCV. Click here for more information about Achillion's ongoing clinical trials.
Hepatitis C is a worldwide epidemic affecting more than 170 million individuals. Click to learn more about this disease.
No upcoming events at this time.
Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors
Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")